PMID- 22608076
OWN - NLM
STAT- MEDLINE
DCOM- 20130401
LR  - 20220317
IS  - 1872-6240 (Electronic)
IS  - 0006-8993 (Linking)
VI  - 1461
DP  - 2012 Jun 21
TI  - The conditioned medium of murine and human adipose-derived stem cells exerts 
      neuroprotective effects against experimental stroke model.
PG  - 87-95
LID - 10.1016/j.brainres.2012.04.033 [doi]
AB  - This study investigated the possible ameliorative effects of adipose-derived stem 
      cells-conditioned medium (ASC-CM) on experimental ischemic stroke. In vivo 
      ischemic stroke was induced in mice after 2h of middle cerebral artery occlusion 
      (MCAO) followed by 22 h reperfusion. Culture of SH-SY5Y human neuroblastoma cells 
      with 100 muM glutamate for 24h was used as an in vitro neuronal apoptosis model. 
      Intracerebroventricular (i.c.v.) administration of 30- and 100-fold concentrated 
      murine ASC-CM 1h prior to MCAO resulted in a dose-dependent reduction in the 
      infarct volume and the brain swelling. The administration of murine ASC-CM 
      immediately after MCAO was also effective, but administration 2h after MCAO was 
      not. Neuroprotective effects of murine ASC-CM were also confirmed in an in vitro 
      model. Pretreatment with 100-fold concentrated murine ASC-CM at 10% of the total 
      culture volume significantly reduced glutamate-induced excitotoxicity in the 
      SH-SY5Y cells. Similar reduction in the MCAO-induced infarction volume was seen 
      following i.c.v. administration of 100-fold concentrated human ASC-CM or murine 
      ASC-CM. In conclusion, ASC-CM appears to exert ameliorative effects on 
      experimental ischemic stroke i\n both in vivo and in vitro models. These findings 
      suggest the feasibility of ASC-CM administration as a therapy for acute stage 
      stroke.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Egashira, Yusuke
AU  - Egashira Y
AD  - Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu 
      Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan.
FAU - Sugitani, Sou
AU  - Sugitani S
FAU - Suzuki, Yukiya
AU  - Suzuki Y
FAU - Mishiro, Keisuke
AU  - Mishiro K
FAU - Tsuruma, Kazuhiro
AU  - Tsuruma K
FAU - Shimazawa, Masamitsu
AU  - Shimazawa M
FAU - Yoshimura, Shinichi
AU  - Yoshimura S
FAU - Iwama, Toru
AU  - Iwama T
FAU - Hara, Hideaki
AU  - Hara H
LA  - eng
PT  - Journal Article
DEP - 20120424
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - *Adipocytes/pathology
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects/physiology
MH  - Cells, Cultured
MH  - *Culture Media, Conditioned/pharmacology
MH  - *Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Injections, Intraventricular
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Neuroprotective Agents/*administration & dosage
MH  - Random Allocation
MH  - *Stem Cells/pathology
MH  - Stroke/pathology/*prevention & control
EDAT- 2012/05/23 06:00
MHDA- 2013/04/02 06:00
CRDT- 2012/05/22 06:00
PHST- 2012/02/23 00:00 [received]
PHST- 2012/04/03 00:00 [revised]
PHST- 2012/04/17 00:00 [accepted]
PHST- 2012/05/22 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2013/04/02 06:00 [medline]
AID - S0006-8993(12)00727-5 [pii]
AID - 10.1016/j.brainres.2012.04.033 [doi]
PST - ppublish
SO  - Brain Res. 2012 Jun 21;1461:87-95. doi: 10.1016/j.brainres.2012.04.033. Epub 2012 
      Apr 24.